SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

NCT05177497 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

19

Enrollment

OTHER

Sponsor class

Conditions

NSCLC, Stage III

Interventions

DRUG: SHR-1701

Sponsor

Shanghai Chest Hospital